Form 4: Boston Scientific Director Acquires Shares

David C. Habiger, a Director at Boston Scientific Corp., acquired 3,800 shares of common stock on May 7, 2026, as part of an annual equity award.

Summary

• David C. Habiger, a Director of Boston Scientific Corp., acquired 3,800 shares of common stock on May 7, 2026.
• This acquisition was part of an annual equity award valued at $215,000, based on the closing stock price on the grant date.
• Following this transaction, Habiger beneficially owns 9,428 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard director equity award and insider acquisition, which generally aligns with management and shareholder interests.

Positives

• Director acquisition of shares indicates confidence in the company's future prospects.
• The equity award is structured to vest upon the next annual stockholder meeting, aligning management interests with long-term shareholder value.

Future Outlook

The equity award vests upon the next annual meeting of stockholders, suggesting a forward-looking incentive tied to continued company performance and governance.

Industry Context

StockSavvy.ai notes that insider stock acquisitions, particularly by directors, are often viewed positively by the market as they signal a belief in the company's intrinsic value and future growth potential within the medical technology sector.

Stakeholder Impact

• Shareholders: The acquisition by a director may be seen as a positive signal of confidence in the company's future performance.
• Employees: Equity awards are a common form of compensation and retention for key personnel.
• Management: The award aligns management's interests with those of shareholders through equity ownership.

Next Steps

• The restricted stock award will vest in full upon the next annual meeting of stockholders.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Equity Award, Director, Common Stock